Operator

Good evening, and welcome to the Humacyte Virtual Investor Event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Humacyte website following the conclusion of the event. I'd now like to turn the call over to your host, Dr. Laura Niklason, Founder, President and Chief Executive Officer of Humacyte. Please go ahead, Laura.

Laura Niklason
Founder, President, CEO & Director

Hi, everyone, and thank you so much for taking the time on a Monday evening to hear our presentation on our recent clinical results, top line results from our V012 study, which was -- which evaluated Humacyte's engineered vessel, the ATEV, in comparison to autogenous fistula for dialysis access. These are our typical disclaimers. What I'd like to start off with so that we're not bearing the lead is that the V012 trial met its primary efficacy endpoint, which -- at this interim analysis, which was the measurement of how many catheter-free days patients who got our vessel, the ATEV had as compared to patients who received a fistula.

This primary -- this interim analysis was done after the first 80 enrolled patients had reached at least 1 year of follow-up. The 80th patient reached 1 year in April of this year, and we received the top line results only very recently. There were -- patients who received ATEV had 91